



My objectives in this course are to:

- Describe in outline a selection of the statistical modelling methods currently employed in analysing small area disease rates (including a basic introduction to Bayesian modelling and 'Markov Chain Monte Carlo' (MCMC) methods)
- Discuss software available to implement these modelling methods using a number of illustrative case studies (including a short basic introduction to the use of the public domain WinBUGS package for Bayesian modelling and links between WinBUGS and the public domain statistical language R)
- > Briefly discuss some **spatio-temporal extensions** to these models
- Provide references to more details about these methods and to extensions and additional approaches



The context of this course

- Area-level data on disease incidence remains more readily available than case-event data. However, the latter is now increasingly becoming accessible and many studies in spatial epidemiology may now be involved with either of these data types and sometimes a mixture of both.
- However, there are important distinctions between the statistical modelling of area data as opposed to that on individual cases and throughout this course we confine ourselves solely to models for data at a group level within geographical areas
- In doing so we must of course remain aware of the problems involved in examining associations between disease incidence and risk factors measured on groups (the so-called ecological fallacy)—we take this as 'gospel' throughout the course









- We will not consider methods (many) and models (fewer) which have been explicitly designed to address a third key area in the analysis of area-level disease incidence—disease clustering
 - ➡ i.e. testing for significant space or/and time elevations in the risk of disease (either unfocussed or focussed) around known suspected (putative) hazards
- There are a whole range of specialised hypothesis tests and related techniques in this area and references are provided to follow these up
- However note that the two areas we intend to cover do indirectly relate to disease clustering — good disease incidence maps often play an important preliminary role in such studies and putative hazards are now sometimes usefully viewed as particular kinds of covariate in models which are similar to those used in correlation studies



Having set the scene for the course, it may be useful to briefly introduce three case studies that we can use throughout to illustrate the methods discussed. These concern:

- ► Leprosy surveillance in the period 1991-1995 in Olinda, N.E. Brazil.
- Incidence of larynx cancer diagnosed during 1982-1991, in the Mersey and West Lancashire districts of N.W England.
- ► Leptospirosis incidence in the city of Rio de Janeiro, Brazil in the period 1997-2002.







Larynx cancer incidence in Mersey and West Lancashire Data consist of 876 cases of larynx cancer diagnosed during 1982-1991, in 144 electoral wards of Mersey and West Lancashire in NW England. Also available are the expected numbers of cases in these wards calculated using external standardisation based on national age- and sex-specific reference rates and population counts from the 1991 census. In addition results of a survey in the Mersey and West Lancashire region which included questions on smoking habits have been used to derive an area-level smoking index for each district ('low', 'medium' or 'high' — i.e. a predominance of non-smokers, moderate smokers or heavy smokers) Finally, a measure of air pollution is available in the form of annual mean levels of particulates in each district estimated from a dispersion model based upon traffic flow.











- Will attempt to briefly review selected topics under following headings using the three illustrative applications where appropriate and introducing computing ideas 'as we go':
 - Preliminaries a tour of statistical/Bayesian modelling
 - Disease mapping
 - Ecological (correlation) studies
 - Further topics in ecological studies
 - Space-time models
 - Concluding remarks
- Time prevents much mathematical detail or anything like an exhaustive coverage. List of selected references provided to help.



A tour of statistical modelling

- The key general purpose conventional method used in estimating the parameters of a statistical model is maximum likelihood
- The joint probability distribution $P(y; \theta)$ when viewed as a function of θ is known as the **likelihood** because under the proposed form of the model it essentially represents 'how likely it is that you would get the particular data y that you observed, given specific values for the parameters θ ' (although note it is **not a probability distribution for** θ)
- > One way to find 'good' estimates for θ is to choose values $\hat{\theta}$ for θ that maximise the likelihood $P(y; \theta)$ i.e. use maximum likelihood estimates (mle)
- ► In general the accuracy of such estimates (i.e. their standard errors) may then be assessed by 'how peaked' the likelihood is at the maximum i.e. by a function of the second derivative of the likelihood evaluated at the maximum ($\theta = \hat{\theta}$). Hypothesis tests may be performed by looking at likelihood ratios ratio of maximised likelihood under null hypothesis to maximised likelihood without it.





$$rac{y}{\hat{ heta}} = rac{(n-y)}{(1-\hat{ heta})}$$
 or $\hat{ heta} = rac{y}{n}$

so the maximum likelihood estimate of theta is just the sample proportion who test +ve (as you would expect!!)



- A simple (non spatial) model for counts of cases of a rare disease (aren't they all!) in n areas also serves as another illustration of the maximum likelihood idea.
- The most basic model is that observed counts of cases $\boldsymbol{y} = (y_1, \ldots, y_n)$ are Poisson distributed $\left(P(y_i) = \frac{\mu_i^{y_i} e^{-\mu_i}}{y_i!}\right)$ with means $\mu_i = e_i \rho_i$, where e_i is the 'expected' number of cases (based on some global reference rate) and ρ_i is the 'relative disease risk' for observation (area) i.
- The 'expected' cases are assumed *known* and taken as $e_i = r\pi_i$ where r is an known overall reference rate for the disease and π_i is the population at risk for each observation. Often this reference rate is stratified for known confounders, such as age and sex i.e. $e_i = \sum_j r_j \pi_{ij}$ (where j is age/sex etc. group)
- So the model can be summarised as: $y_i \sim \text{Poisson}(e_i \rho_i)$ where ρ_i is the relative disease risk for observation *i* compared to the chosen reference rate.





 \blacktriangleright Elementary probability theory then allows us to relate $P(y, \theta)$ to the likelihood:

$$P(\boldsymbol{y}, \boldsymbol{\theta}) = P(\boldsymbol{y}|\boldsymbol{\theta})P(\boldsymbol{\theta})$$

where $P(\theta)$ is called the **prior** probability distribution for the parameters. This prior expresses our **uncertainty about** θ before taking the data into account. It will usually be chosen to be 'non-informative'.

Bayes Theorem then allows derivation of a **posterior** probability distribution for the parameters given the observed data:

$$P(\boldsymbol{\theta}|\boldsymbol{y}) = \frac{P(\boldsymbol{y}|\boldsymbol{\theta})P(\boldsymbol{\theta})}{P(\boldsymbol{y})} = \frac{P(\boldsymbol{y}|\boldsymbol{\theta})P(\boldsymbol{\theta})}{\int_{\boldsymbol{\theta}} P(\boldsymbol{y}|\boldsymbol{\theta})P(\boldsymbol{\theta}) \, d\boldsymbol{\theta}}$$

i.e. 'posterior' is proportional to 'likelihood' \times 'prior' — the denominator is just a **normalising constant** independent of the parameters (but unfortunately difficult to calculate because it involves a 'nasty' multi-dimensional integral)



statements



- Let's return to our earlier simple example to clarify these ideas.
- Recall we were estimating the incidence of a disease in the general population from a random sample of n individuals, each of whom are tested for the disease, and y is the number who test +ve.
- > As before, let θ be probability an individual has the disease, then the likelihood for y is a binomial distribution:

$$P(y|\theta) = \binom{n}{y} \theta^y (1-\theta)^{n-y}$$

Suppose take a prior for θ as U(0,1) i.e. $P(\theta) = 1$ for $0 \le \theta \le 1$ (this says θ equally likely to be anywhere in the (0,1) range)









- For example suppose $f(\theta)$ is some function of the parameters of interest (e.g. a prediction from the model)
- ► Let $\theta^{(1)}, \ldots, \theta^{(n)}$ where $\theta^{(i)} = (\theta_1^{(i)}, \ldots, \theta_p^{(i)})$, denote n samples from the posterior $P(\theta|y)$.
- \blacktriangleright Then if n is large enough:

$$\hat{f}(\boldsymbol{\theta}) = \mathsf{E}\left[f(\boldsymbol{\theta})|\boldsymbol{y}\right] \approx \frac{1}{n}\sum_{i=1}^{n}f(\boldsymbol{\theta}^{(i)})$$

- That's nice! But the problem is then how to simulate samples from the posterior? Direct sampling from $P(\theta|y)$ is difficult (because you don't know what it is!). But *indirect* sampling from a Markov Chain (MC) with $P(\theta|y)$ as its stationary (equilibrium) distribution is feasible.
- Sequence $\{\theta^{(i)}\}$ is an MC if $P(\theta^{(i+1)}|\theta^{(1)},\ldots,\theta^{(i)}) = P(\theta^{(i+1)}|\theta^{(i)})$ i.e. next value $\theta^{(i+1)}$ depends only on current value $\theta^{(i)}$ and not previous values. Subject to certain conditions, MCs gradually 'forget' their initial value and converge to a **stationary distribution** (overall probability of taking any value remains same and this is independent of the original starting value). Subsequent values of the chain are then samples from this stationary distribution
- Hence construct an MC with a stationary distribution identical to the posterior and use values from that MC chain after a sufficiently long *burn in* as simulated samples from the posterior. This is called **Markov Chain Monte Carlo** (MCMC)



Markov Chain Monte Carlo (MCMC) methods

- The Metropolis-Hastings algorithm constructs a Markov Chain to converge to the target distribution by sampling a candidate for the next value of the chain from a proposal distribution and then either accepting it or rejecting it according to a acceptance probability which depends upon the proposal distribution, the target distribution, the current state of the chain and the candidate value
- The proposal distribution can have any form subject to certain regularity conditions. It will be chosen to be appropriate to the particular target distribution required and so that it is easy to sample from

Markov Chain Monte Carlo (MCMC) methods

- For Given a target distribution, $p(\theta|y)$, the Metropolis-Hastings proceeds as follows:
 - \blacksquare Set i=0 and choose arbitrary starting values ${m heta}^{(0)}$ for ${m heta}$
 - → Sample a candidate, $\boldsymbol{\theta}^{(*)}$, for the next state of the chain given the current state $\boldsymbol{\theta}^{(i)}$ from a pre-selected proposal distribution, $q(\boldsymbol{\theta}^{(*)}|\boldsymbol{\theta}^{(i)})$

$$\alpha\left(\boldsymbol{\theta}^{(i)}, \boldsymbol{\theta}^{(*)}\right) = \min\left\{1, \frac{p(\boldsymbol{\theta}^{(*)}|\boldsymbol{y})q(\boldsymbol{\theta}^{(i)}|\boldsymbol{\theta}^{(*)})}{p(\boldsymbol{\theta}^{(i)}|\boldsymbol{y})q(\boldsymbol{\theta}^{(*)}|\boldsymbol{\theta}^{(i)})}\right\}$$

(note target distribution appears only as a ratio, so unknown constant of proportionality involved in $p(\theta|y)$ cancels)

- → Sample u such that $u \sim U(0, 1)$. If $u \leq \alpha(\boldsymbol{\theta}^{(i)}, \boldsymbol{\theta}^{(*)})$ then set $\boldsymbol{\theta}^{(i+1)} = \boldsymbol{\theta}^{(*)}$, else set $\boldsymbol{\theta}^{(i+1)} = \boldsymbol{\theta}^{(i)}$
- \implies Set i = i + 1 and return to step 2 for a new candidate (repeat 1000's of times)







- After sufficient 'burn in' successive samples θ⁽ⁱ⁾ = (θ₁⁽ⁱ⁾, ..., θ_p⁽ⁱ⁾) formed from general Metropolis-Hastings or some variant such as Gibbs Sampling settle down to samples from a markov chain with stationary distribution P(θ|y).
- Samples from marginal posteriors (e.g. $P(\theta_j | \boldsymbol{y})$) are approximated by simply picking out the values for one parameter from the samples ignoring the other parameters.
- Characteristics concerning a parameter are then estimated from the marginal posterior samples via their sample equivalents (e.g. mean, mode, median, standard deviation, quantiles etc.)

A tour of Bayesian modelling

- As said, important issues in MCMC to ensure good estimates are convergence ('burn-in' required) and mixing (required number of samples after convergence)
- There are formal ways to assess convergence (see references) but essential point is that samples for any parameter should be a random scatter about a stable mean value. Note convergence is to a target distribution not to a single value. Check convergence by several long runs and widely different starting values (multiple chains). Statistics such as 'R hat' help to assess whether the chains have converged (Rule of thumb: its value should be < 1.2 for each parameter)</p>
- After convergence, sufficient samples required to ensure posterior variance is estimated accurately. Again formal techniques exist (see references). A useful statistic is the MC standard error for each parameter. Ideally want MC error small in relation to posterior st. dev. (Rule of thumb: run simulation until MC error for each parameter < 5% of sample (posterior) st. dev)



MCMC methods make Bayesian modelling of complex situations involving many parameters a practical feasibility. Use is now widespread (non spatial as well as spatial). In summary the full Bayesian MCMC approach is:

- Choose appropriate (joint) probability model (likelihood) for the data— $P(y|\theta)$
- \blacktriangleright Choose appropriate (joint) prior for the parameters— $P(\theta|\gamma)$
- \blacktriangleright Choose appropriate (joint) hyperprior for the hyperparameters— $P(\gamma)$
- ► Use MCMC (Gibbs Sampling or general Metropolis-Hastings) to generate numerous samples $(\theta, \gamma)^{(i)}, i = 1, ..., n$ from posterior $P(\theta, \gamma | y)$ using:

 $P(\boldsymbol{\theta}, \boldsymbol{\gamma} | \boldsymbol{y}) \propto P(\boldsymbol{y} | \boldsymbol{\theta}) P(\boldsymbol{\theta} | \boldsymbol{\gamma}) P(\boldsymbol{\gamma})$

Estimate any characteristic of interest involving one or more of the parameters or hyperparameters by the equivalent characteristic of the posterior samples



► In the notation we have been using, we can represent this as a Bayesian model by taking the parameters as: $\boldsymbol{\theta} = (\alpha, \beta, \sigma)$ and the data $\boldsymbol{y} = (y_1, \ldots, y_{24})$ to consist of independent observations with $P(y_i | \boldsymbol{\theta}) \sim \mathsf{N}(\alpha + \beta \mathsf{age}_i, \sigma^2)$ so that:

$$P(\boldsymbol{y}|\boldsymbol{ heta}) = \prod_{i=1}^{24} P(y_i|\boldsymbol{ heta})$$

- \blacktriangleright As priors for both α and β we use Normal distributions with zero means and large variances.
- As a prior for σ^2 we take $\tau = \frac{1}{\sigma^2}$ (known as the **precision**) to have a Gamma distribution with mean 1 and a large variance.
- These choices are pretty standard for this situation and represent minimally informative priors. Note in this case the priors do not involve hyperparameters

	A tour of Bayesian modelling
n WinBUGS we require the following specification	on:
Model for(i in 1:N){	
Y[i] \sim dnorm(mu[i], tau) $$ # normal distribution for	or data, mean mu, precision tau
$mu[i] \leftarrow alpha + beta * age[i] # linear model for$	r mean mu
}	
alpha \sim dnorm(0, 1.0E-6) $$ # diffuse normal prior	or for alpha
beta \sim dnorm(0, 1.0E-6) $$ # diffuse normal prior	for beta
tau \sim dgamma(.001, .001) $$ # vague gamma pri	ior for tau
sigma \leftarrow 1/sqrt(tau) # st. deviation for Y derive Data	ed from tau
list(N = 24,Y = c(3.5,1.9,,3.3),age = c(46, 20,	.,50))
nitial values for the MCMC sampler	
list(alpha = 0, beta = 0, tau = 1)	





				A to	our of Bay	esian modelling/
The corresp	onding sumr	nary statistic	cs were:			
	posterior	mean	sd	2.5%	median	97.5%
	$P(\alpha \boldsymbol{y})$	1.27800	0.224300	0.83170	1.27900	1.73800
	$P(\beta \boldsymbol{y})$	0.05265	0.005406	0.04178	0.05259	0.06324
	$P(\sigma \boldsymbol{y})$	0.34600	0.055730	0.25660	0.33930	0.47360
Results from	the convent	tional regres	sion were:			
		parameter estimate sd				
		α	1.27			
		β	0.05	2625 0.00	05192	
		σ	0.33	4000		
Note that ch	anging the n	nodel from l	$P(y_i \boldsymbol{\theta}) \sim$	N(lpha+etaage	(\mathbf{e}_i,σ^2) to o	ne with a different
distributiona	l assumption	n, or with a n	nean which i	s a non-linea	r function of	the parameters mea
that rearees	ion connot b	a used (a G	Mic thon ro	auirod) How	vovor in tho	Bayesian case it me







Basic Disease Mapping Model

 \blacktriangleright We have already introduced the basic model for observed counts y_i i.e.:

 $y_i \sim \text{Poisson}(\mu_i) = \text{Poisson}(e_i \rho_i)$

where e_i is the known 'expected' number of cases (based on some global reference rates within suitable population strata) and ρ_i is the unknown relative risk in area i compared to the chosen reference rates.

- Such a model is reasonable for a relatively rare and non-infectious disease with assumed constant risk within each area × strata combination. Sometimes for less rare conditions a Binomial formulation might be appropriate, but we focus on the more common Poisson case here.
- Note the model for μ_i can be expressed equivalently as: $\log \mu_i = \log e_i + \theta_i$ where θ_i denotes log relative risk (i.e. $\theta_i = \log \rho_i$ or $\rho_i = \exp(\theta_i)$).



Random effects models for disease mapping

- In other words the data exhibit extra-Poisson variation or overdispersion (because of the within area variation the variance in disease counts is greater than that which would be expected from a Poisson distribution)
- > One way to allow for **overdispersion** in the Poisson model is to take the ρ_i as **random** effects.
- Treating these parameters as random (rather than fixed) effects introduces an extra source of variability (a latent effect) into the model to capture the impact of unknown or unobserved confounding factors
- Essentially they allow the estimate of relative risk for each area to 'borrow strength' from data in other areas leading to a dampening or smoothing of the raw SMRs (often referred to shrinkage)







Poisson-Gamma Bayesian model for disease mapping

- To fit this model could use **empirical Bayes** which involves obtaining point estimates for the hyperparameters $\hat{\psi}$ and $\hat{\phi}$ from global aspects of the data and then proceeding as if these quantities are known (see Clayton *al*, 1987)
- ► But better to use the full hierarchical Bayesian framework (we have the technology!!) i.e. specify a hyperprior for ψ and for ϕ and then derive a full posterior for these hyperparameters together with the relative risks $\rho = (\rho_1, \dots, \rho_n)$ via use of MCMC applied to:

 $P(\boldsymbol{\rho}, \psi, \phi | \boldsymbol{y}) \propto P(\boldsymbol{y} | \boldsymbol{\rho}) P(\boldsymbol{\rho} | \psi, \phi) P(\psi) P(\phi)$

 \blacktriangleright In practice suitable hyperpriors for ψ and ϕ would be diffuse exponential distributions







Model extensions for spatial structure

- The model considered so far allows for overdispersion in the Poisson distribution of counts y_i (via the random effects) but it does not allow for explicit spatial dependence between the y_i. This may also be present (e.g. arising through lesser variability of rates in neighbouring densely populated urban areas as opposed to sparsely populated rural areas, or an infectious aetiology)
- > Can include such dependence by splitting random effect θ_i in the Poisson-log normal model into a **spatially unstructured** and a **spatially structured** term
- ► θ_i is replaced by $\alpha + \phi_i + \nu_i$ where α is the mean log relative risk over all areas (i.e. our earlier μ_{θ}), ϕ_i a zero mean spatially unstructured (or exchangeable) log relative risk of area *i* compared to the map as a whole, and ν_i is corresponding spatially structured (**non-exchangeable**) random effect.
- > This model is often termed a convolution model

Model extensions for spatial structure

A typical choice for the spatially structured prior for ν_i is a conditional intrinsic Gaussian autoregressive model (CAR) (see Besag *et al*, 1995) i.e.:

$$\nu_i | \nu_{j \neq i} \sim \mathsf{N}\left(\frac{\sum_{j \neq i} w_{ij} \nu_j}{\sum_{j \neq i} w_{ij}}, \frac{\sigma_{\nu}^2}{\sum_{j \neq i} w_{ij}}\right)$$

here w_{ij} are suitable **adjacency weights** for the areas and the new hyperparameter σ_{ν} controls the strength of local spatial dependence.

- > Often w_{ij} are taken as simple binary values— $w_{ij} = 1$ if area *i* has common boundary with area *j*, $w_{ij} = 0$ otherwise.
- Similar to before, the prior for φ_i is φ_i ~ N(0, σ²_φ). The prior for α is now taken as α ~ U(-∞, +∞) to allow for the fact that the CAR is **improper** (has undefined mean) and so a 'sum to zero' constraint needs to applied to the ν_i.







- Refers to investigations where the focus is on examining associations between disease incidence and risk factors measured on groups (we have already mentioned the so-called ecological fallacy)
- As usual there are various approaches (see references). But we focus on extensions to the Bayesian hierarchical models we employed in disease mapping
- Following the basic model development we then consider a number of further issues concerned with such models and their interpretation, for example the handling of censored values and missing values, predictive distributions and correction for specification bias and measurement error

Bayesian Ecological Models

➤ We use a straightforward extension of the disease mapping model discussed earlier to include p covariates (x_{i1}..., x_{ip}) measured in each area i i.e. y_i ~ Poisson(µ_i) = Poisson(e_iρ_i) with:

$$\log \mu_i = \log e_i + \alpha + \sum_{j=1}^p \beta_j x_{ij} + \phi_i + \nu_i$$

note overall relative risks are now $\rho_i = \exp(\alpha + \sum_j \beta_j x_{ij} + \phi_i + \nu_i)$ and $\exp(\alpha + \phi_i + \nu_i)$ is the **residual relative risk** after 'correcting' for the covariates.

- ▶ Priors and hyperpriors relating to ϕ_i , ν_i and α are as before. Non-informative Normal priors (zero mean large variances) are adopted for $\beta = (\beta_1, \dots, \beta_p)$.
- Then use MCMC to obtain samples from $P(\alpha, \beta, \phi, \nu, \tau_{\phi}, \tau_{\nu} | \boldsymbol{y})$ where hyperparameters $\tau_{\phi} = 1/\sigma_{\phi}^2$ and $\tau_{\nu} = 1/\sigma_{\nu}^2$ again refer to the precisions of the priors for spatially unstructured and spatially structured random effects ϕ_i and ν_i .



There is therefore no clear evidence of the nitrate effect, but it cannot be entirely ruled out. Remember — absence of evidence is not evidence of absence


Bayesian Ecological Models

- The preceding model allows for differences in areas through a combination of unstructured and spatially structured random effects, but the nature of the relationships between relative risk and the ecological covariates is assumed homogeneous over the study region—there is no local variation in β
- An alternative perspective on spatial heterogeneity is to allow non constant covariate coefficients over the study region i.e. allow β to be area specific. In the case of a single covariate, x_i , a suitable model might be:

$$\log \mu_i = \log e_i + \alpha + \beta_i x_i + \phi_i + \nu_i$$

with exchangeable priors $\beta_i \sim \text{Normal}(\mu_\beta, \sigma_\beta^2), i = 1, \dots, n$ and other priors as before. Here μ_β represents the average relationship with x_i over the region

Note identifiability may be a problem in such a model (inability to uniquely distinguish between certain parameters because an exactly identical set of outcomes can arise from more than one set of parameter values). Some parameter constraints may be needed.

Bayesian Ecological Models

If the area specific relationships in the previous model are expected to be differentiated in a spatially distinct pattern (i.e. similar relationships are spatially clustered) then we can use a model such as:

 $\log \mu_i = \log e_i + \alpha + \beta x_i + \beta_i x_i + \phi_i + \nu_i$

with the β_i assumed to be spatially dependent i.e. non-exchangeable priors $\beta_i \sim CAR(\sigma_\beta^2), i = 1, \dots, n.$

The βx_i term (with prior as $\beta \sim U(-\infty, +\infty)$) is included in the model to represent the overall global relationship since the CAR is improper and a sum to zero constraint will need to be imposed on β_i . The β_i therefore now represent deviations from the overall relationship.

Bayesian Ecological Models

- Clearly identifiability problems are compounded with such a model and further issues arise relating to potential confounding between the spatially dependent area-specific coefficients β_i and the spatially dependent random effects ν_i.
- For these reasons alternative less direct formulations have been suggested which avoid the CAR and instead incorporate a multivariate set of underlying unstructured random effects which induce spatial dependence in the β_i and the ν_i by being linked to them via scaled adjacency weighting systems (see Congdon, 2003; Leyland *et al*, 2000).
- Such an approach is particularly useful when models involving area-specific coefficients for more than one explanatory variable need to be considered, since the CAR formulation is difficult to extend to this case.



Leprosy surveillance in Olinda (Brazil) 1991-1995

- As a more extended example of the use of Bayesian ecological models let us consider application of the basic model (with non area specific covariate coefficients) to the data on leprosy incidence from Olinda in Brazil. This example will also allow us to explore how our previous Bayesian models can be extended to handle censored (and missing) data values
- There is a priori reason to believe that numbers of leprosy cases will be higher in the poorer and more socially deprived areas. To allow for this we include a single covariate x_i in the model the proportion of heads of household with monthly income below one minimum legal wage (approximately US\$80).
- Expected cases e_i in each area are derived from the population at risk and the global leprosy detection rate over the whole study area
- \blacktriangleright In the CAR definition, w_{ij} are taken as the standard binary adjacency weights.



			Lo	eprosy s	survei	llance il	n Olin	da 1991	-1995
MCMC (1	0,000 sar	nples wit	h 'burn in	' of 5000	and th	inning of	10) pro	ovides foll	owing
posterior	mean esti	mates fo	r a select	ion of the	param	neters			
	Model 1991-1995 std.		\hat{lpha}		\hat{eta}				
			mean	95% cre	ed int	mean 95% cred int			
			-0.5	(-0.6,	-0.2)	0.4	(0.1	1, 1.2)	J
		Мс	odel	$\hat{\sigma}_{\phi}$		$\hat{\sigma}_{ u}$]	
				mean	sd	mean	sd		
		1991-1	995 std.	0.4	0.1	1.0	0.2		













- Using this 60% cut-off as a working assumption (could obviously experiment with alternatives) we then have a need for a model that can incorporate censoring and this provides an example of how relatively straightforward it is to handle censored values in the Bayesian framework more generally
- The basic model for the leprosy counts remains the same, but now data is: $(y, y^*) = (y_1, \ldots, y_m, y^*_{m+1}, \ldots, y^*_n)$, where y^*_i refer to the censored data values in the areas where the deprivation indicator exceeds 60% (for convenience we reorder the data by deprivation score).
- So now likelihood is: $P(y_1, \ldots, y_m | \boldsymbol{\theta}) P(Y_{m+1} \ge y_{m+1}^*, \ldots, Y_n \ge y_n^* | \boldsymbol{\theta})$ rather than simply $P(y_1, \ldots, y_n | \boldsymbol{\theta})$ as before
- ► MCMC then provides posterior: $P(\theta, y_{m+1}, \ldots, y_n | \boldsymbol{y}, \boldsymbol{y}^*)$ i.e. the joint distribution of the parameter set in the model θ together with estimates for the n m censored values given the m exactly observed data values \boldsymbol{y} and the n m censoring points \boldsymbol{y}^*



Results	for stand	ard mod	del vers	us cei	nsoring	for le	prosy i
M	odel		$\hat{\alpha}$			\hat{eta}	
		mean	90% cre	ed int	mean	90%	cred int
1991-19	995 std.	-0.5	(-0.6,	0.2)	0.4	(-0.1, 1.2)	
1991-19	995 cens.	-0.9	(-1.2, ·	0.6)	1.9	(1.	1, 2.7)
	Мо	del	$\hat{\sigma}_d$		$\hat{\sigma}_{\nu}$,	1
			mean	sd	mean	sd	
	1991-199	95 std.	0.4	0.1	1.0	0.2	
	1991-199	95 cens.	0.5	0.1	0.9	0.2	



Leprosy surveillance in Olinda 1991-1995

- Treatment of the suspected under-detections via censoring would appear to have been relatively successful in producing more realistic estimates of true cases in the poorer areas. The estimated total of 1991-1995 cases is now 1590, as opposed to 1135 observed and predicted from non-censored model— more similar to the 1,766 cases actually detected in 1996-2000.
- Model can be used to estimate number of under-detections in each area. If such under-detection estimates had been available in 1995 then improved surveillance could have been targeted in areas where particularly bad under-detection had occurred with knowledge of the suspected numbers of missed detections in those areas
- Example illustrates how the statistical modelling of disease rates can directly lead to the identification of valuable public health responsive action. Application discussed concerns leprosy control, but the methods may equally well be applied in surveillance of other diseases where under-reporting of cases is a potential problem.

Handling missing data values

- Also worth noting at this point that missing data values (as opposed to censored values) are also very simply handled in the Bayesian framework
- The data vector is then $(\boldsymbol{y}, \boldsymbol{y}^{(*)}) = (y_1, \ldots, y_m, y_{m+1}^{(*)}, \ldots, y_n^{(*)})$, where the y_i refer to actual data values and the $y_i^{(*)}$ refer to missing data values (for convenience we assume the data are ordered accordingly)
- The model (i.e. likelihood, priors, hyperpriors) remains the same but now MCMC provides samples from $p(\theta, y^{(*)}|y)$ the joint posterior distribution of the set of real parameters in the model θ together with the n m missing values $y^{(*)}$, given the m actual observed data values y
- Point estimates, standard errors etc. for any particular missing values are then obtained from the marginal posterior distribution for this quantity, in exactly the same way as they would be for any other parameter of the model

Adjusting Larynx Cancer risk in Mersey & West Lancashire for smoking

- A further example of using an ecological model is provided by returning to the larynx cancer data and recalling that we have a three level indicator for the prevalence of smoking in each of these districts (1='low', 2='moderate', 3= 'high'). We now incorporate this categorical factor into the earlier spatially structured Poisson-log normal model.
- The resulting WinBUGS model can also be extended to predict the excess number of cases associated with smoking in any particular area and the probability that reducing smoking levels to 1 in that area will lead to reduction of more than 15 cases. This requires the use of the idea of a Bayesian predictive distribution.

Bayesian predictive distributions

- > Suppose that the original data consists of observations y associated with p covariates $X = (x_1, \ldots, x_p)$ in a Bayesian model that involves a set of parameters θ
- ➤ Further suppose that we wish to predict the response y* at a new set of covariate values (x₁^{*},...,x_p^{*}). Then the relevant predictive distribution is defined as:

$$P[y^*|(x_1^*,\ldots,x_p^*),\boldsymbol{y},\boldsymbol{X}] = \int_{\boldsymbol{\theta}} P[y^*|(x_1^*,\ldots,x_p^*),\boldsymbol{\theta}] P[\boldsymbol{\theta}|\boldsymbol{y},\boldsymbol{X}] d\boldsymbol{\theta}$$

- i.e. the predictive distribution averages over the uncertainty in the parameter values as reflected by the posterior distribution
- In fact we have already used this idea in predicting the values of censored in the Olinda example and in our discussion of handling missing data values





Further topics in ecological studies

But one should always appreciate the potential problems and biases associated with aggregate level studies:

- Problems of spatial scale—typically the health, exposure and population data are obtained from different sources and this can lead to problems of imprecise geographical matching and data aggregation. The choice of aggregation unit needs to trade off between data precision, the ability to detect localised patterns of risk and the scale over which an environmental risk factor may be expected to operate.
- Problems of confounding—an omitted variable which is related to both the disease and to some of the included risk factors. E.g. area-level socio-deprivation is strongly correlated with many diseases, but it also coincides with such things as industrial sites, busy roads and smoking.



Further topics in ecological studies

- Problems of specification bias—the difference between individual and group level relationships between disease incidence and risk caused by non-constant exposure to risk within the group
 - For example, suppose that we are considering a single risk factor and that at the *individual level* the relative risk of contracting a disease given a level of exposure x is exp(α + βx) (i.e. a log-linear relationship as in the ecological models we have considered)
 - → Then the relationship between group relative risk and mean exposure (μ_x) at an *area-level* will *not* be exp($\alpha + \beta \mu_x$) unless the exposure of all individuals in the area is the same (i.e. all have exposure μ_x)
 - Instead this relationship will be a weighted average of the function $\exp(\alpha + \beta x)$ over values of x with the weights reflecting the probabilities of individuals within the region receiving exposure levels x



Adjusting for specification bias in ecological studies

E.g. For a single covariate and given a sub-sample of the exposures of M individuals in each of the N areas a relevant **WinBUGS** model might be something like:

```
for (i in 1 : N) {
    y[i] ~ dpois(mu[i]) # observed counts
    log(mu[i]) ← log(e[i])+alpha+beta*mu.x[i]+pow(beta,2)*sigmasq.x[i]/2 # mean model
    for (j in 1 : M) {
        x[i,j] ~ dnorm(mu.x[i],tau.x[i]) # exposure sub-sample
    }
    mu.x[i] ~ dnorm(0, 1.0E-6) # mean area-level exposure
    tau.x[i] ~ dgamma(.01,.01) # precision area-level exposure
    sigmasq.x[i] ← 1/tau.x[i] # area-level exposure variance
    }
    alpha ~ dnorm(0, 1.0E-6) # prior for alpha
    beta ~ dnorm(0, 1.0E-6) # prior for beta
where, for simplicity of presentation we have ignored the random effect terms that would
```

usually be additionally included





Errors-in-variables modelling

For continuous exposures classical measurement error is often described by the reliability coefficient:

$$\rho = \frac{\sigma_{true}^2}{\sigma_{true}^2 + \sigma_{err}^2}$$

where σ_{true}^2 is the variance of the true exposure and σ_{err}^2 reflects the variance of measurement errors.

- The average size of errors for categorical exposures can be described by a matrix of misclassification probabilities p_{jk}, where p_{jk} is the conditional probability that a subject is classified as level k given that they are truly exposed to level j
- Given information on these quantities the ecological models that we have described can be adjusted to allow for measurement errors in the explanatory variables

Adjusting Larynx Cancer risk for air pollution

- In a previous model we adjusted the risk of larynx cancer according to a three level smoking factor. We now include as an additional covariate a measure of air pollution—the annual mean levels of particulates in each area estimated from a dispersion model based on traffic flow
- From previous validation studies the reliability coefficient for these air pollution estimates is:

$$\rho = \frac{\sigma_{true}^2}{\sigma_{true}^2 + \sigma_{err}^2} = 0.71$$

We consider a WinBUGS model that includes the air pollution covariate and at the same time allows for errors in observed values of this covariate in accord with the above reliability coefficient

Adjusting lar	ynx cancer risk for air pollution & measurement error
he relevant WinBUGS mode	el is:
for (i in 1 : N) {	
y[i] ~ dpois(mu[i])	# Poisson likelihood for observed counts
log(mu[i]) <- log(e[i])+alpha	+betal[smoke[i]]+beta2*truepoll[i]+phi[i]+nu[i] #model for mean
phi[i] ~ dnorm(0, tau.phi)	<pre># prior for unstructured random effects</pre>
truepoll[i] ~ dnorm(mu.true,t	au.true) # distribution of true exposure
poll[i] ~ dnorm(truepoll[i],t	au.err) # distribution of measurement error
rholocaladj[i] <- exp(phi[i]+	nu[i]) # R risks compared to overall risk in study area after
}	# adjusting for smoking and air pollution
<pre>nu[1:N] ~ car.normal(adj[],wei</pre>	ghts[],num[],tau.nu) # CAR prior for structured random effects
alpha ~ dflat()	# uniform prior for alpha
betal[1] <- 0	<pre># set betal[1] as the reference smoking level</pre>
beta1[2] ~ dnorm(0, 0.0001)	<pre># diffuse normal prior for betal[2]</pre>
	<pre># diffuse normal prior for betal[3]</pre>
	<pre># diffuse normal prior for beta2</pre>
tau.phi [~] dgamma(0.5, 0.0005)	
tau.nu ⁻ dgamma(0.5, 0.0005)	
sigma.phi <- sqrt(1/tau.phi) sigma.nu <- sqrt(1/tau.nu)	# st dev of unstructured rand effects # st dev of structured rand effects
mu.true ~ dnorm(0, .00001)	# st dev of structured rand effects # diffuse normal hyperprior for mu.true
) # diffuse gamma hyperprior for tau.true
sigmasg.true <- 1/tau.true	<pre># variance of true measurements</pre>
rho <- 0.71	<pre># reliability coefficient</pre>
	(1-rho)/rho # variance of measurement error



- So far we have only considered models involving spatial outcomes, but obviously the evolution over time of such outcomes may also be of considerable interest
- There exist a broad class of models that may be used in modelling (and perhaps forecasting) spatio-temporal disease incidence by area
- We focus here only on illustrating the **potential** for spatio-temporal modelling of small area disease rates, restricting our discussion to fairly simple extensions to the Bayesian ecological models that we have used in the purely spatial context
- In particular we do not explore in any detail the various alternative formulations of space-time interaction in such models — this is a substantive topic and we can only touch upon the issues here (for more details see Knorr-Held and Besag, 1998)



To complete the specification diffuse gamma hyperpriors are assumed for precisions corresponding to all hyperparameters i.e. for $\tau_{\phi} = 1/\sigma_{\phi}^2$, $\tau_{\nu} = 1/\sigma_{\nu}^2$ and $\tau_{\delta} = 1/\sigma_{\delta}^2$



auto-regression may be preferred if one is interested in *predicting* future disease rates.
Note that identifiability problems arise with these kinds of formulations and will need to be addressed by imposing constraints on some parameters.



- Where interest focusses on modelling trends in the relative risk relative to the reference levels, then one might impose a stronger parametric structure on the temporal effects
- E.g. a linear trend (identical across all areas) would correspond to a model:

$$\log \mu_{it} = \log e_{it} + \alpha + \phi_i + \nu_i + \gamma t$$

with $\gamma \sim \text{Normal}(0, \sigma_{\gamma}^2)$ and all other priors as before.

To allow for differentiated trends between areas, e.g. with some falling more or some less than the global trend one could specify an area specific growth rate via:

$$\log \mu_{it} = \log e_{it} + \alpha + \phi_i + \nu_i + \gamma_i t$$

with exchangeable priors $\gamma_i \sim \text{Normal}(\mu_\gamma, \sigma_\gamma^2)$, where μ_γ is the overall average growth rate.

> identifiability remains an issue and some parameter constraints may need to be imposed

Spatio-Temporal Models

- If such trends are expected to be differentiated in a spatially distinct pattern (i.e. similar falls or rises are spatially clustered) then the γ_i might be assumed to be spatially dependent
- For example we could take $\gamma_i \sim CAR(\sigma_{\gamma}^2)$ in which case we would also need a γt term in the model to represent the global trend with $\gamma \sim U(-\infty, +\infty)$ since the CAR is improper and a sum to zero constraint on γ_i will need to be imposed.
- > so overall the model that results is:

 $\log \mu_{it} = \log e_{it} + \alpha + \phi_i + \nu_i + \gamma t + \gamma_i t$

with γ_i now representing deviations from the overall γ .

 Again identifiability is an issue and some parameter constraints may need to be imposed



- The modelling options for spatial and temporal structure in the area-time interactions \u03c6_{it} are very wide, since autocorrelations over areas may be combined in various ways with those over time.
- Knorr-Held (2000) discusses four types of interaction schemes, ranging from independence of all interactions to complete space/time dependence in the interactions



- Finally note that variability in relative risks over both space and time may be caused by changing impacts of social and other risk variables.
- All the space time models discussed can be extended to include ecological covariates $(x_{it1} \dots, x_{itp})$ relating to areas, to time periods or to both
- A very wide range of formulations is possible, depending upon whether covariate measures are available only at each time point (spatially constant), or only for each area (constant in time), or for each space-time combination
- Associated covariate model coefficients can likewise be modelled as globally constant, varying only over time, varying only over space or varying over both time and space.



Leptospirosis incidence in Rio de Janeiro 1997-2002

- As an example of the use of spatio-temporal models we consider the data comprising diagnosed cases of Leptospirosis by year for the period 1997-2002 (total of 367 cases) in 157 districts of the city of Rio de Janeiro.
- Area specific expected values e_i are taken as constant over time and based on the district populations in the 2001 census, using as a reference rate the overall disease incidence for the six years as a proportion of 6 × the total 2001 population in the study region
- ▶ We also include two area specific deprivation covariates from the 2001 census— x_{i1} (proportion of families with income of less than one minimum wage) and x_{i2} (proportion of the population living in favelas)
- A further area and time specific covariate x_{it3} is maximum annual rainfall in the years 1997-2002 interpolated to districts from observations recorded at 32 weather stations dotted across the city. This provides some indication of the risk of floods in each district in the year in question.









- ➤ We have focussed on Bayesian models there are a range of alternatives which do not use a Bayesian framework (e.g. Prentice *et al*, 1995; Yasui *et al*, 1997)
- A further approach has been the use of Geostatistical models (e.g. see Webster *et al*, 1994; Diggle *et al*, 1998)
- I said at the outset that I was not going to discuss methods explicitly designed to detect disease clustering, either in space or in space and time, or at focussed or unfocussed locations. There is a substantial literature on this important subject and I have included a special section of references for those who wish to follow it up

	Contact Details
Professor Trevor C Bailey School of Engineering, Computing and Mathematics Harrison Building Exeter University Exeter	
EX4 4QE U.K.	
Tel: +44 (0)1392725223	
Email: T.C.Bailey@ex.ac.uk WWW: http://www.secam.ex.ac.uk/	

References

On relevant books and reviews

Brooks S (1998), Markov Chain Monte Carlo and its application, *Journal of Royal Statistical Society*, Series D, 47, 69-100.

Cressie N., (1993), *Statistics for Spatial Data*, Wiley.

Congdon, P. (2001), *Bayesian Statistical Modelling*, Wiley.

Congdon, P. (2003), Applied Bayesian Modelling, Wiley.

Fotheringham A., Brunsdon C., Charlton M., (2000), *Quantitative Geography*, Sage.

Elliot P, Cuzick J, English D, Stern R (eds.) (1992), *Geographic and Environmental Epidemiology: Methods for small area studies*, Oxford University Press.

Elliot P, Wakefield J., Best N. and Briggs D. (eds.) (2000) *Spatial Epidemiology: Methods and Applications*, Oxford University Press.

Gilks W Richardson S, Spiegelhalter D (eds.) (1996), *Markov Chain Monte Carlo in Practice*, Chapman and Hall.

Goldstein H., (1995), *Multilevel Statistical Models*, Edward Arnold.

Journal of the Royal Statistical Society, Series A. (2001). 164 (1). Special issue on the analysis and interpretation of disease clusters and ecological studies.

Lawson A., Biggeri A., Böhning D., Lesaffre E., Viel J-F., Bertollini R. (eds.), (1999), *Disease Mapping and Risk Assessment for Public Health*, Wiley.

Lawson A. (2001) Statistical Methods in Spatial Epidemiology, Wiley.

Spiegelhalter D, Thomas A, Best N, Gilks W., (1997), *BUGS: Bayesian Inference using Gibbs Sampling*, MRC Biostatistics Unit, Cambridge, UK.

On Disease Mapping and Ecological (correlation) studies

Armstrong, B.G. (1998). Effect of measurement error on epidemiological studies of environmental and occupational exposures. *Occupational and Environmental Medicine*, 55, 651-6.

Bernardinelli L., Pascutto C., Best N.G., Gilks W.R., (1997), Disease mapping with errors in covariates, *Statistics in Medicine*, 16, 741-752.

Bernardinelli L., Clayton D., Pascutto C., Montmoli C., Ghislandi M., (1995), Bayesian analysis of space-time variation in disease risk, *Statistics in Medicine*, 14, 2433-2443.

Bernardinelli L., Clayton D., Montomoli C., (1995), Bayesian Estimates of disease maps: how important are priors? *Statistics in Medicine*, 14, 2411-2431.

Besag, J., York, J. and Mollie, A. (1991). Bayesian image restoration, with two applications in spatial statistics, *Ann. Inst. Statist. Math.*, 43, 1-59.

Best, N.G. and Wakefield, J.C. (1999)., Accounting for inaccuracies in population counts and case registration in cancer mapping studies, *Journal of the Royal Statistical Society*, Series A,162, 363-82.

Brunsdon C., Fotheringham S., Charlton M., (1998), Geographically weighted regression-modelling spatial non-stationarity, *Journal of Royal Statistical Society*, Series D, 47, 431-444.

Casetti E., 1992, Bayesian regression and the expansion method, *Geograhical analysis*, 24, 58-74.

Clayton D., Kaldor J., (1987), Empirical Bayes estimates of age-standardised relative risks for use in disease mapping, *Biometrics*, 43, 671-681.

Diggle P., Tawn J., Moyeed R., (1998), Modelbased Geostatistics, *Journal of Royal Statistical Society*, Series C, 47, 299-350.

Knorr-Held L., Besag J., (1998), Modelling risk

from a disease in time and space, *Statistics in Medicine*, 17, 2045-2060.

Lawson A., Biggeri A., Dreassa E., (1999), Edge effects in disease mapping, in Lawson A., Biggeri A., Böhning D., Lesaffre E., Viel J-F., Bertollini R. (eds.), *Disease Mapping and Risk Assessment for Public Health*, Wiley, 85-97.

Leyland A., Langford I., Rasbash J. and Goldstein H. (2000), Multivariate spatial models for event data, *Statistics in Medicine*, 19, 2469-78.

Muller H.G., Stadtmuller U., Tabnak F. (1997), Spatial smoothing of geographically aggregated data, with application to the construction of incidence maps, *Journal of the American Statistical Association*, 92, 437, 61-71.

Pascutto, C., Wakefield, J.C., Best, N.G., Richardson, S., Bernardinelli, L., Staines, A. and Elliott, P. (2000), Statistical issues in the analysis of disease mapping data, *Statistics in Medicine*, 19, 2593-19.

Plummer M, Clayton D (1996), Estimation of population exposure in ecological studies, *Journal of Royal Statistical Society*, Series B, 58, 113-126.

Prentice R, Sheppard L (1995), Aggregate data studies of disease risk factors, *Biometrika*, 82, 113-125.

Richardson S, Green P (1997), On Bayesian analysis of mixtures with an unknown number of components, *Journal of Royal Statistical Society*, Series B, 59, 731-792.

Schalttmann P, Bohning D (1993), Mixture models and disease mapping, *Statistics in Medicine*, 12, 1943-1950.

Schalttmann P Bohning D Dietz E (1996), Covariate adjusted mixture models with the program DismapWin, *Statistics in Medicine*, 15, 919-929.

Wakefield, J.C. and Elliott, P. (1999). Issues

in the statistical analysis of small-area health data. *Statistics in Medicine*, 18, 2377-99.

Waller L, Carlin B, Xia H, Gelfand A (1997), Hierarchical spatio-temporal mapping of disease rates, *Journal of the American Statistical Association*, 92, 607-617.

Webster R, Oliver M, Muir K, Mann J (1994),

On Cluster Investigation (general and focussed)

185

ation, 92, 21-32.

Alexander F.E., Boyle P. (eds.) (1996), *Methods for Investigating Localised Clusters of Disease*, IARC Scientific Publication 135, International Agency for Research on Cancer, Lyon, France.

Anderson N H, Titterington D M (1997), Some methods for investigating spatial clustering, with epidemiological applications, *Journal Royal Statistical Society*, Series A, 160, 87-105.

Besag J, Newell J (1991), The detection of clusters in rare diseases, *Journal of Royal Statistical Society*, Series A, 154, 143-155.

Besag J, Kooperberg C (1995), On conditional and intrinsic autoregressions, *Biometrika*, 82, 733-746.

Bithell J (1995), The choice of test for detecting raised disease risk near a point source, *Statistics in Medicine*, 14, 2309-2322.

Cuzick J, Edwards R (1990), Spatial clustering for inhomogeneous populations, *Journal of Royal Statistical Society*, Series B, 52, 73-104.

Hills M, Alexander F (1989), Statistical methods used in assessing the risk of disease near a source of possible environmental pollution: a review, *Journal of Royal Statistical Society*, Series A, 152, 353-363.

Jacquez G.M. (1996), Disease Cluster statistics for imprecise space-time locations, *Statistics in Medicine*, 15, 873-885.

Jacquez G.M. (1996), A k-nearest neighbour test for space-time interaction, *Statistics in Medicine*, 15, 1935-1949.

Knox E.G., (1964), The detection of space-time interactions, *Applied Statistics*, 13, 25-29.

Kulldorff M, Hjalmars U (1999), The Knox method and other tests for space-time interaction, *Biometrics*, 55, 544-552.

Kulldorf M, Feuer EJ, Miller BA, Freedman LS (1997), Breast cancer clusters in the northeast United States: A geographic analysis, *American*

Journal of Epidemiology, 146, 161-170.

Kulldorf M (1997), A spatial scan statistic, *Communications in Statistics - Theory and Methods*, 26, 1481-1496.

Kriging the local risk of a rare disease from a reg-

ister of diagnoses, Geographical Analysis, 26, 168-

for spatial disease rates: an estimating function ap-

proach, Journal of the American Statistical Associ-

Yasui Y, Lele S (1997), A regression method

Kulldorf M, Nagarwalla N (1995), Spatial disease clusters: detection and inference, *Statistics in Medicine*, 14, 799-810

Lawson A., Clark A., (1999), Markov Chain Monte Carlo methods for clustering in case event and count data in spatial epidemiology, in Halloran E., Greenhouse J. (eds.), *Statistics and Epidemiology: Environment and Health*, Springer-Velag.

Lawson A. (1995), Markov Chain Monte Carlo methods for putative polution source problems in environmental epidemiology, *Statistics in Medicine*, 14, 2473-2486.

Lawson A, Viel J (1995), Tests for directional space-time interaction in epidemiological studies, *Statistics in Medicine*, 14, 2383-2392.

Lawson A. (1993), On the analysis of mortality events around a prespecified fixed point, *Journal of the Royal Statistical Society*, Series A, 156, 363-377.

Potthoff R.F., Whittinghill M., (1966), Testing for Homogeneity in the POisson distribution, *Biometrika*, 53, 167-190.

Stone R., (1988), Investigations of excess environmental risks around putative sources: statistical problems and a proposed test, *Statistics in Medicine*, 7, 649-660.

Tango T (1995), A class of test for detecting 'general' and 'focussed' clustering of rare diseases, *Statistics in Medicine*, 14, 2323-2334.

Waller L., Lawson A (1995), The power of focussed tests to detect disease clustering, *Statistics in Medicine*, 14, 2291-2308.

Waller L., Turnbull (1993), The effect of scale on tests for disease clustering, *Statistics in Medicine*, 12, 1869-1884.